Real-World Use of BTK Inhibitors in Chronic Lymphocytic Leukemia - Episode 2

Translating BTK Inhibitor Data into Clinical Decision-Making

,

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss how to use data for BTK inhibitors to inform clinical decisions in chronic lymphocytic leukemia.

EP. 1: Factors for Selecting a BTK Inhibitor vs Other Regimens in CLL
Now Viewing
EP. 2: Translating BTK Inhibitor Data into Clinical Decision-Making
EP. 3: The SEQUOIA Trial of Zanubrutinib vs BR in Previously Untreated CLL/SLL
EP. 4: Matching-Adjusted Indirect Comparisons of BTK Inhibitors in CLL
EP. 5: Real-World Safety Data for BTK Inhibitors in CLL from EHA 2024
EP. 6: Future Treatment Directions and Ongoing Trials in CLL

Related Content:

Fred Hutch Cancer CenterChronic Lymphocytic Leukemia
Dr Dorritie on Acalabrutinib With/Without Obinutuzumab in Treatment-Naive CLL
Dr Banerjee on Deciding Between CAR T-Cell Therapy and Bispecific Antibodies in Myeloma
Dr Banerjee on the Benefit of Bispecific Antibody Dose Reduction in Multiple Myeloma